Barclays analyst Carter Gould raised the firm’s price target on Eli Lilly to $590 from $500 and keeps an Overweight rating on the shares post the Q2 report. The analyst says Mounjaro is approaching a $4B run-rate, giving the firm increased conviction in is $10B 2024 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
